🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

8 recruiting trials

for Intermediate and High-risk Non-muscle Invasive Bladder Cancer

Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer NCT07646145Phase 21 site📍 Taiyuan Shanxi Province Cancer Hospital · Tests: Disitamab Vedotin, Mitomycin C (MMC) A Phase I Clinical Study of SHR-2005 Intravesical Instillation in the Treatment of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC) NCT06108492Phase 11 site📍 Shanghai Shanghai Hengrui Pharmaceutical Co., Ltd. · Tests: SHR-2005 Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC) NCT05825950n/a2 sites📍 Dallas📍 San Antonio University of Texas Southwestern Medical Center Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) NCT05037279Phase 36 sites📍 Vancouver📍 Kingston📍 Toronto Verity Pharmaceuticals Inc. · Tests: Bacillus Calmette-Guerin: Strain Russian BCG-I, Bacillus Calmette-Guerin: Strain TICE Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer NCT06441110Phase 31 site📍 Fuzhou Fujian Medical University Union Hospital · Tests: Tislelizumab in Combination with Bacillus Calmette-Guérin A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC NCT06971614Phase 29 sites📍 Queen Creek📍 Los Angeles📍 Orlando ImmVira Pharma Co. Ltd · Tests: T3011 Predicting BCG Response NCT04564781n/a6 sites📍 Los Angeles📍 Los Angeles📍 San Francisco Cedars-Sinai Medical Center A Multicenter Prospective Cohort Study on Monitoring Recurrence of Urothelial Carcinoma Based on Detection of Urinary Microscopic Residual Disease (MRD) NCT06991868n/a1 site📍 Beijing Peking University First Hospital
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy